Atrium Therapeutics, Inc. RNA R2K
Atrium Therapeutics, Inc., a biopharmaceutical company, focuses on delivering ribonucleic acid (RNA) therapeutics to the heart to transform the care for people living with cardiomyopathies. The company's development stage product candidates include ATR 1072, a siRNA-based therapy targeting PRKAG2 for the treatment of PRKAG2 syndrome; and ATR 1086, a siRNA-based therapy targeting PLN for the treatment of PLN cardiomyopathy. It also focuses on pipeline to treat a range of genetic and cardiac diseases. The company was incorporated in 2025 and is headquartered in San Diego, California.
READ MORE ›Market & Price
Valuation
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Growth (CAGR)
PROS
- Compounding revenue at 38.1% over 5 years.
CONS
- Earnings shrank at -550.5% CAGR over 5 years.
* The pros and cons are auto-generated from financial metrics.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth
No fundamental data available for this stock.
Figures from the latest reported periods. CAGR is computed across the displayed window (quarterly CAGR is annualised assuming 4 quarters per year).
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | RNA Atrium Therapeutics, Inc. R2K | 13.00 | - | $222.37M | - | -32.47% | - | 38.09% | -550.50% |
| 2 | LLY Eli Lilly and Company SPX | 1,105.00 | 39.21 | $985.37B | 0.63% | 38.44% | 107.46% | 31.69% | 48.96% |
| 3 | JNJ Johnson & Johnson SPX | 225.33 | 26.11 | $542.42B | 2.38% | 23.13% | 26.42% | 5.60% | 14.32% |
| 4 | UNH UnitedHealth Group Incorporated SPX | 380.31 | 28.66 | $345.38B | 2.32% | 9.60% | 12.18% | 11.35% | -15.69% |
| 5 | MRK Merck & Co., Inc. SPX | 118.72 | 33.44 | $293.22B | 2.86% | 20.66% | 18.94% | 3.12% | 7.93% |
| 6 | TMO Thermo Fisher Scientific Inc. SPX | 492.51 | 27.11 | $183.03B | 0.38% | 9.17% | 13.52% | -0.27% | -1.19% |
| 7 | AMGN Amgen Inc. NDXSPX | 336.79 | 23.42 | $181.77B | 2.99% | 18.02% | 101.32% | 11.77% | 5.58% |
| 8 | GILD Gilead Sciences, Inc. NDXSPX | 134.43 | 18.29 | $166.90B | 2.44% | 22.92% | 43.36% | 2.57% | 22.83% |
| 9 | ISRG Intuitive Surgical, Inc. NDXSPXAI | 424.64 | 51.53 | $150.39B | - | 15.96% | 17.23% | 17.39% | 29.26% |
Quarterly Results
Figures in USD.
| Metric | Dec 2024 | Mar 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|
| Revenue | 2.97M | 1.57M | 859.00K | 19.64M |
| Cost of Revenue | - | - | - | - |
| Gross Profit | - | - | - | - |
| Operating Expenses | 47.22M | 9.03M | 48.89M | 36.91M |
| Operating Income | -44.25M | -7.45M | -48.03M | -17.28M |
| EBITDA | -44.19M | -7.40M | -47.91M | -17.13M |
| Interest Expense | - | - | - | - |
| Pretax Income | -44.24M | -7.45M | -48.03M | -16.63M |
| Tax Provision | 1.95M | - | 34.00K | - |
| Net Income | -46.20M | -7.45M | -48.07M | -16.63M |
| Diluted EPS | - | -0.44 | - | -0.97 |
| R&D Expense | - | 6.94M | - | 16.66M |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|
| Revenue | 9.76M | 10.90M | 18.62M |
| Cost of Revenue | - | - | - |
| Gross Profit | - | - | - |
| Operating Expenses | 16.15M | 24.11M | 95.43M |
| Operating Income | -6.39M | -13.22M | -76.81M |
| EBITDA | -6.25M | -13.05M | -76.49M |
| Interest Expense | - | - | - |
| Pretax Income | -6.38M | -13.22M | -76.83M |
| Tax Provision | 0 | 11.91M | -142.00K |
| Net Income | -6.38M | -25.12M | -76.68M |
| Diluted EPS | -0.37 | -1.47 | -4.48 |
Compounded Sales Growth
| 5 Years: | 38.09% |
| 1 Year: | 1,148.30% |
Compounded Profit Growth
| 5 Years: | -550.50% |
| 1 Year: | - |
Stock Price Performance
| 1 Year: | -11.86% |
| 6 Months: | - |
| 3 Months: | -11.86% |
| 1 Month: | +0.08% |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|
| Total Assets | 10.29M | 7.19M | 278.35M |
| Current Assets | 856.00K | 483.00K | 272.85M |
| Cash & Equivalents | - | - | 270.00M |
| Inventory | - | - | - |
| Receivables | 751.00K | 0 | - |
| Total Liabilities | 80.91M | 68.29M | 71.07M |
| Current Liabilities | 33.80M | 26.80M | 41.80M |
| Long Term Debt | - | - | - |
| Total Debt | 9.85M | 6.80M | 3.67M |
| Total Equity | -70.62M | -61.11M | 207.29M |
| Shares Outstanding | 17.11M | 17.11M | 17.11M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|
| Operating Cash Flow | 56.39M | -22.55M | -41.13M |
| Investing Cash Flow | -320.00K | -266.00K | -1.45M |
| Financing Cash Flow | -56.07M | 22.82M | 42.57M |
| Capital Expenditure | -320.00K | -266.00K | -1.45M |
| Free Cash Flow | 56.07M | -22.82M | -42.57M |
| Net Change in Cash | - | - | - |
Ratios (Annual)
Figures in %.
| Metric | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|
| Gross Margin % | - | - | - |
| Operating Margin % | -65.4% | -121.3% | -412.6% |
| Net Margin % | -65.4% | -230.5% | -411.9% |
| ROE % | 9.0% | 41.1% | -37.0% |
| ROCE % | 27.2% | 67.4% | -32.5% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | Price (T.Rowe) Associates Inc | 9.08% | 1.55M | $20.19M |
| 2 | Blackrock Inc. | 7.05% | 1.21M | $15.67M |
| 3 | RA Capital Management, L.P. | 5.05% | 864.10K | $11.23M |
| 4 | Vanguard Capital Management LLC | 3.66% | 626.87K | $8.15M |
| 5 | TIG Advisors, LLC | 3.55% | 607.55K | $7.90M |
| 6 | Pentwater Capital Management Lp | 3.52% | 602.65K | $7.83M |
| 7 | O'Connor Alternative Investments LLC | 3.38% | 578.01K | $7.51M |
| 8 | Sessa Capital IM, L.P. | 3.22% | 551.39K | $7.17M |
| 9 | Goldman Sachs Group Inc | 2.05% | 349.95K | $4.55M |
| 10 | Farallon Capital Management LLC | 2.04% | 349.36K | $4.54M |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for RNA